Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Candesartan on Cardiovascular Events After DES Implantation
NCT00139386Phase 4Completed
- Sponsor
- Kumamoto University
- Start
- Oct 2005
- Primary completion
- Apr 2009
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of candesartan in hypertension (HTN), coronary artery disease (CAD) and heart failure (HF) (2 arms), sponsored by Kumamoto University. Primary endpoint: Composite of any cause mortality and cardiovascular events at 3 years. Started Oct 2005; status: completed.
02
Drugs
candesartan
03
Conditions
hypertension (HTN)coronary artery disease (CAD)heart failure (HF)
Beyond the preview
Go deeper on NCT00139386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139386.